{"id":"cross-over-boceprevir-treatment","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Anemia"},{"rate":"20-30","effect":"Dysgeusia (taste perversion)"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Fatigue"},{"rate":"15-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4868590","moleculeType":"Unknown","molecularWeight":"504.67"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Boceprevir directly inhibits the HCV NS3/4A serine protease, an enzyme essential for processing the HCV polyprotein into functional viral proteins. By blocking this protease, the drug prevents viral maturation and replication. The 'cross-over' designation typically refers to a trial design where patients switch between treatment regimens.","oneSentence":"Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral replication by preventing the cleavage of HCV polyproteins.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:55.117Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotype 1"}]},"trialDetails":[{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT00959699","phase":"PHASE2","title":"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"HIV Infections, Hepatitis C, HCV Infection","enrollment":99},{"nctId":"NCT00423670","phase":"PHASE2","title":"Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01","conditions":"Chronic Hepatitis C","enrollment":765}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SCH 503034","Victrelis"],"phase":"phase_3","status":"active","brandName":"Cross-Over Boceprevir Treatment","genericName":"Cross-Over Boceprevir Treatment","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral replication by preventing the cleavage of HCV polyproteins. Used for Chronic hepatitis C virus (HCV) infection, genotype 1.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2011-07-18T00:00:00.000Z","mah":"Merck Sharp  Dohme Ltd","brand_name_local":"Victrelis","application_number":"EMEA/H/C/002332"}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}